Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice

C. D. Heldermon, E. Y. Qin, K. K. Ohlemiller, E. D. Herzog, J. R. Brown, C. Vogler, W. Hou, J. L. Orrock, B. E. Crawford, M. S. Sands

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Mucopolysaccharidosis type IIIB (MPS IIIB) or Sanfilippo Syndrome type B is a lysosomal storage disease resulting from the deficiency of N-acetyl glucosaminidase (NAGLU) activity. We previously showed that intracranial adeno-associated virus (AAV)-based gene therapy results in partial improvements of several aspects of the disease. In an attempt to further correct the disease, MPS IIIB mice were treated at 2-4 days of age with intracranial AAV2/5-NAGLU (IC-AAV), intravenous lentiviral-NAGLU (IV-LENTI) or the combination of both (BOTH). The BOTH group had the most complete biochemical and histological improvements of any treatment group. Compared with untreated MPS IIIB animals, all treatments resulted in significant improvements in motor function (rotarod) and hearing (auditory-evoked brainstem response). In addition, each treatment group had a significantly increased median life span compared with the untreated group (322 days). The combination arm had the greatest increase (612 days), followed by IC-AAV (463 days) and IV-LENTI (358 days). Finally, the BOTH group had nearly normal circadian rhythm measures with improvement in time to activity onset. In summary, targeting both the systemic and central nervous system disease of MPS IIIB early in life appears to be the most efficacious approach for this inherited metabolic disorder.

Original languageEnglish
Pages (from-to)913-921
Number of pages9
JournalGene therapy
Volume20
Issue number9
DOIs
StatePublished - Sep 2013

Keywords

  • MPS IIIB
  • Sanfilippo
  • behavioral

Fingerprint

Dive into the research topics of 'Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice'. Together they form a unique fingerprint.

Cite this